As Chief Scientific Officer (CSO), Mavys oversees the technical evolution and platform-ready integration of Destina’s core chemistry. Holding a PhD in Pharmacy with a focus on medicinal chemistry and HDAC inhibitors, her career spans years of process optimization and scale-up in the biotech industry. Since 2013, Mavys has led the multidisciplinary effort to adapt DGL-Tech™ for industry-leading systems, ensuring absolute data integrity and single-nucleotide resolution across all applications.